In the year since its hack, 23andMe has lost all of its value and most of its governing board — and somehow, things just keep ...

Me announces 40% workforce reduction and cancellation of therapeutic programs following year of security breaches and ...

In the ever-evolving tech industry, a transformative shift is taking place as women ascend to prominent leadership roles, ...

( NewsNation) — Genetic testing company 23andMe has faced a series of struggles this year, culminating in end-of-year mass ...

Meanwhile, Hims & Hers tackles the GLP-1 shortage with a new app; Eli Lilly releases data on tirzepatide efficacy; 23andMe faces privacy concerns; and more.

What is the most Silicon Valley thing about your morning routine? Zoë, you go first. Zoë Schiffer: Pretty much the first ...

Me just dropped some major news in a tough year for the genetic testing company. After months of financial challenges, data ...

CEO Anne Wojcicki has said she intends to take the company private and is not considering third-party takeover proposals.

The genetic testing company 23andMe hasn't been doing so hot lately, watching its share price plummet more than 70% this year ...

The restructuring arrives during a period of turmoil at California-based 23andMe, which has recently included a high-profile ...

The genetic testing firm will also close its therapeutics arm. CEO Anne Wojcicki said the cuts are necessary to “focus on the ...